Sign in

Private company

REPLICEL LIFE SCIENCES INC.

Canadian biological products company based in Vancouver Bc2

In its 2023 annual report (Form 20-F) the company says: “We are a regenerative medicine company focused on developing autologous cell therapies that treat functional cellular deficits. We are also developing a programmable injector device and related consumables designed for dermal injections of cells as currently approved other products such as dermal fillers, toxins, enzymes, drugs, and biologics such as fat transfer, platelet rich plasma, antibodies, etc.”15

Last updated Oct 21, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersVancouver, Canada2
  • Incorporated inBritish Columbia, Canada3
  • Business addressSuite 900 - 570 Granville Street, Vancouver Bc, A1 V6C 3P13
  • Filer categoryNon-accelerated filer3
  • Legal formCorporation2
  • LEI8945007P51J5A3XROX562
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered address900-885 West Georgia Street, V6C 3H1 Vancouver, Canada2
  • Registered withBC Registry Services, C09136932

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45678-$1.4M in 2022−67% since 2016
-$6.0M-$4.0M-$2.0M02016: -$4.3M-$4.3M20162017: -$6.0M-$6.0M2017+40%2018: -$2.7M-$2.7M2018−55%2019: -$2.9M-$2.9M2019+9%2020: -$1.4M-$1.4M2020−54%2021: -$2.3M-$2.3M2021+70%2022: -$1.4M-$1.4M2022−39%
Net income45678-$743.2K in 2022−83% since 2016
-$8.0M-$6.0M-$4.0M-$2.0M02016: -$4.3M-$4.3M20162017: -$6.0M-$6.0M2017+41%2018: -$2.8M-$2.8M2018−54%2019: -$3.0M-$3.0M2019+8%2020: -$1.6M-$1.6M2020−47%2021: -$4.1M-$4.1M2021+158%2022: -$743.2K-$743.2K2022−82%
Fiscal year20162017201820192020202120222023
Research and development1.1M CAD8624.0K CAD8
Selling, general and admin1.5M CAD81.1M CAD8
Operating income-4.3M CAD4-6.0M CAD5-2.7M CAD6-2.9M CAD7-1.4M CAD8-2.3M CAD8-1.4M CAD8
Income tax0 CAD80 CAD8
Net income-4.3M CAD4-6.0M CAD5-2.8M CAD6-3.0M CAD7-1.6M CAD8-4.1M CAD8-743.2K CAD8
Earnings per share (diluted)-0 CAD/shares7-0 CAD/shares8-0 CAD/shares8-0 CAD/shares8
Shares (weighted, diluted)32.5M shares837.8M shares8

Compare REPLICEL LIFE SCIENCES INC. with another company

Corporate structure

REPLICEL LIFE SCIENCES INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of REPLICEL LIFE SCIENCES INC.

  • Andrew Schutte Filed SC 13D/A on REPLICEL LIFE SCIENCES INC., latest Apr 20, 2023 (3 filings since Jun 2, 2022)
  • Jamie Myles Mackay Filed SC 13D/A on REPLICEL LIFE SCIENCES INC., latest Jan 5, 2023 (2 filings since Sep 29, 2022)
  • MAINPOINTE PHARMACEUTICALS, LLC Filed SC 13D/A on REPLICEL LIFE SCIENCES INC., latest Dec 21, 2021
  • REPLICEL LIFE SCIENCES INC. Vancouver, British Columbia, Canada

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What REPLICEL LIFE SCIENCES INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net2.4K CAD8 Dec 31, 20223.3K CAD8 Dec 31, 2021−25.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents413.0K CAD8 Dec 31, 2022221.2K CAD8 Dec 31, 2021+86.7%

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorAndrew Schutte named Dec 20, 2021 to Dec 16, 202410
  • Executive OfficerBen Austring named Jan 6, 2023 to Dec 16, 202410
  • Executive Officer, DirectorDavid Hall named Dec 20, 2021 to Dec 16, 202410
  • Executive OfficerDavid Kwok named Dec 16, 202410
  • Executive OfficerKevin McElwee named Dec 16, 202410
  • Executive OfficerROLF HOFFMANN named Dec 20, 2021 to Mar 16, 202311
  • Executive OfficerSIMON MA named Dec 20, 2021 to Mar 16, 202311
  • DirectorGary Boddington named Dec 20, 2021 to Dec 16, 202410
  • DirectorJamie Mackay named Dec 16, 202410
  • DirectorLee Buckler named Dec 20, 2021 to Dec 16, 202410
  • DirectorPeter Lewis named Dec 20, 2021 to Dec 16, 202410
  • DirectorPETER LOWRY named Dec 20, 2021 to Mar 16, 202311

Former names

  • NEWCASTLE RESOURCES LTD.Dec 1, 2008 to Jun 13, 20113
  • PAN AMERICAN GOLD CORPMay 25, 2004 to Nov 28, 20083
  • TRI LATERAL VENTURE CORPNov 27, 2002 to May 10, 20043

Filings

64 filings to the SEC since October 2021: 3 annual reports, 6 large holders, 7 private raises, 48 other. The latest 20:

  1. Dec 16, 2024D EDGAR
  2. Mar 20, 20246-K EDGAR
  3. Nov 30, 20236-K EDGAR
  4. Oct 24, 20236-K EDGAR
  5. Oct 19, 20236-K EDGAR
  6. Oct 4, 20236-K EDGAR
  7. Sep 14, 20236-K EDGAR
  8. Sep 7, 20236-K EDGAR
  9. Aug 30, 20236-K EDGAR
  10. Aug 29, 20236-K EDGAR
  11. Aug 17, 20236-K EDGAR
  12. Aug 10, 20236-K EDGAR
  13. May 31, 20236-K EDGAR
  14. May 18, 20236-K EDGAR
  15. May 2, 202320-F EDGAR
  16. Apr 20, 2023SC 13D/A SCHEDULE 13D/A EDGAR
  17. Mar 21, 20236-K EDGAR
  18. Mar 16, 2023D EDGAR
  19. Feb 23, 20236-K EDGAR
  20. Feb 23, 20236-K EDGAR

The 64 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Andrew SchutteSC 13D/A, 3 filings Jun 2, 2022 to Apr 20, 202312
  • Jamie Myles MackaySC 13D/A, 2 filings Sep 29, 2022 to Jan 5, 202313
  • MAINPOINTE PHARMACEUTICALS, LLCSC 13D/A, 1 filing Dec 21, 202114

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 26, 2024Raised $223,665 in a private offering of equity Form D: 2 investors so far Form D
  2. Mar 14, 2023Raised $740,778 in a private offering of equity Form D: 5 investors so far Form D
  3. Feb 1, 2023Raised $9,196 in a private offering of equity Form D: 1 investor so far Form D
  4. Jan 17, 2023Raised $86,942 in a private offering of equity Form D: 2 investors so far Form D
  5. Dec 30, 2022Raised $558,837 in a private offering of equity Form D: 2 investors so far Form D
  6. May 4, 2022Raised $592,728 in a private offering of equity Form D: 2 investors so far Form D
  7. Dec 17, 2021Raised $777,659 in a private offering of equity Form D: 1 investor so far Form D

SEC filer profile

How REPLICEL LIFE SCIENCES INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARREPLICEL LIFE SCIENCES INC.1
  • CIK0001205059
  • Filer statusNon-accelerated filer1
  • Incorporated inBritish Columbia, Canada1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressSuite 900 - 570 Granville Street, Vancouver Bc, A1 V6C 3P11
  • Phone604-248-86931
  • Shares outstanding65,001,560 as of Apr 25, 20238
  • On EDGAR sinceNov 27, 20021
  • Filings422 in all: 6-K (302), D (23), 20-F (22), CORRESP (15), UPLOAD (12), SC 13D/A (11), NT 20-F (8), 20-F/A (7)1
    All 17 form types

    20FR12G/A (7), SC 13D (7), S-8 (2), 20FR12G (1), 6-K/A (1), CT ORDER (1), D/A (1), S-8 POS (1), SC 14F1 (1)

  • Latest filingsAnnual report (20-F) May 2, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15